141.64  2.94 (2.12%)		10-03 16:00
Open: 139 High: 143.09 Volume: 2,325,181		Pre. Close: 138.7 Low: 138.855 Market Cap: 40,158(M)

Short term
Mid term
Targets	6-month :	167.12	1-year :	195.2
Resists	First :	143.08	Second :	167.12
Pivot price	128.42
Supports	First :	129.3	Second :	120.77
MAs	MA(5) :	134.2	MA(20) :	127.74
	MA(100) :	119.4	MA(250) :	125.74
MACD	MACD :	3.5	Signal :	2
%K %D	K(14,3) :	93.8	D(3) :	84.6
RSI	RSI(14): 75.1
52-week	High :	153.83	Low :	96.43

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ A ] has closed above the upper band by 6.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 113.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	143.18 - 143.6	143.6 - 144.07
Low:	137.57 - 138.09	138.09 - 138.66
Close:	140.72 - 141.51	141.51 - 142.39

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Sat, 04 Oct 2025
Penobscot Investment Management Company Inc. Lowers Stock Holdings in Agilent Technologies, Inc. $A - MarketBeat

Sat, 04 Oct 2025
Janney Montgomery Scott LLC Has $14.17 Million Stock Position in Agilent Technologies, Inc. $A - MarketBeat

Thu, 02 Oct 2025
Barclays Maintains Agilent Technologies (A) Equal-Weight Recommendation - Nasdaq

Thu, 02 Oct 2025
Agilent Technologies, Inc.'s (NYSE:A) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Yahoo Finance

Wed, 01 Oct 2025
Agilent Technologies Inc. (A) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade

Wed, 01 Oct 2025
Agilent Technologies Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	284 (M)
Shares Float	282 (M)
Held by Insiders	0.2 (%)
Held by Institutions	92.6 (%)
Shares Short	3,200 (K)
Shares Short P.Month	2,880 (K)

EPS	4.28
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	22.45
Profit Margin	17.9 %
Operating Margin	23.1 %
Return on Assets (ttm)	8.3 %
Return on Equity (ttm)	19.8 %
Qtrly Rev. Growth	10.1 %
Gross Profit (p.s.)	12.59
Sales Per Share	23.95
EBITDA (p.s.)	6.49
Qtrly Earnings Growth	21.6 %
Operating Cash Flow	1,500 (M)
Levered Free Cash Flow	903 (M)

PE Ratio	33.01
PEG Ratio	0
Price to Book value	6.3
Price to Sales	5.91
Price to Cash Flow	26.76

Dividend	0.25
Forward Dividend	0
Dividend Yield	0.1%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.